Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anticarcinogenic medicine composition

A technology for anticancer drugs and compositions, which can be used in drug combinations, antineoplastic drugs, pharmaceutical formulations, etc., and can solve problems such as treatment failure and enhancement

Inactive Publication Date: 2005-10-12
SHANDONG LANJIN PHARMA +1
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The latter often leads to increased resistance of tumor cells to nitrosourea anticancer drugs, resulting in treatment failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Put 90 mg of PLGA (a copolymer of lactic acid and glycolic acid) with a molecular weight of 10,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, add 10 mg of butylthionine thioxime (BSO), re-shake and vacuum Dry to remove organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer drug composition containing 10% by weight of butylthionine (BSO). The drug release time of the anticancer drug composition in the physiological saline in vitro is 15-20 days, and the drug release time in the mouse subcutaneous is 30-40 days. All are percentages by weight.

Embodiment 2

[0083] As described in Example 1, the difference is that the anticancer active ingredients are:

[0084] a) 1-50% by weight of ammonium metavanadate, ethylene glycol maleate, cadmium ions, trivalent organic arsenic, glutathione disulfide, tetramethylthiuram disulfide, aminotriazole, Butylthionine thioxime, diuretic acid, curcumin, puffylic acid, S-hexyl glutathione, neopodophyllotoxin, N-[2-(dimethylamino)ethyl]acridine-4 -carboxamide, 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indenol[2,1-c]quinol-7-dihydrochloride, bis-dioxo Piperazine propane, hexacyclic nucleocamptothecin, or tetraacenecarboxamide; or

[0085] b) 1-50% by weight of 7-amino-indazole, canavanic acid, aminoguanidine, S-methylisothiourea, S-methylisothiourea sulfate, S-2-amino-5- (2-Aminoimidazol-1-yl)pentanoic acid, L-N 5 -(1-iminoethyl)ornithine, N-monomethyl-L-arginine acetate, N-amino-arginine methyl ester, N-ω-amino-arginine, amino-arginine acid, NG-amino-L-arginine, L-amino-arginine-p-aminoanilide,...

Embodiment 3

[0087]Put 8 mg of pharmaceutical excipients (EVAc) into a container, add 100 ml of dichloromethane to dissolve and mix well, add 20 mg of aminotriazole, re-shake, and then vacuum dry to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain an anticancer drug composition containing 20% ​​by weight of aminotriazole. The drug release time of the anticancer drug composition in the physiological saline in vitro is 14-24 days, and the drug release time in the mouse subcutaneous is 20-35 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An anticancer composite medicine applied locally is prepared from anticancer nitrosource medicine or its analog, the glutathion synthetase depressant and / or the nitrogen oxide synthetase depresant for destroying the DNA repairing function in cell and lowering the tolerance of tumor cells to nitrosource medicine or its analog, and the biocompatible and biodegradable high-modular polymer as medicinal additive.

Description

(1) Technical field [0001] The invention relates to an anticancer drug composition, which belongs to the technical field of drugs. (2) Background technology [0002] The treatment of solid tumors mainly includes surgery, radiotherapy and chemotherapy. Among the various chemotherapeutic drugs used, nitrosourea anticancer drugs have obvious effects and have been widely used in various malignant tumors. However, further research found that the DNA repair function in many tumor cells increased significantly after the treatment. The latter often leads to enhanced resistance of tumor cells to nitrosourea anticancer drugs, resulting in treatment failure. [0003] It has recently been found that inactivating or inhibiting intracellular DNA repair proteins can enhance the sensitivity of some tumor cells to chemotherapy, see Dolan et al. The role of ""Cancer Research" 51 pp. 3367-3372 (1991) (Dolan et al., Cancer Res., 51, 3367-3372, 1991). However, blood vessels, connective tissu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61P35/00
Inventor 孔庆忠孙娟刘恩祥张婕
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com